Category
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc....
As of Nov. 6, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up...
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying CyberArk Software Ltd. (NASDAQ:CYBR). “That is a terrific situation, I've liked it for many, many years,” he added. On Oct. 29, Cantor Fitzgerald analyst Jonathan Ruykhaver maintained CyberArk...
